| Literature DB >> 35008441 |
Marina Martínez-Carmona1,2, Fernando Lucas-Ruiz1,2, Alejandro Gallego-Ortega1,2, Caridad Galindo-Romero1,2, María Norte-Muñoz1,2, María José González-Riquelme1,2, Francisco J Valiente-Soriano1,2, Manuel Vidal-Sanz1,2, Marta Agudo-Barriuso1,2.
Abstract
Ly6c is an antigen commonly used to differentiate between classical and non-classical monocytes/macrophages. Here we show its potential as a marker of the mouse vasculature, particularly of the retinal vascular plexuses. Ly6c was immunodetected in several tissues of C57BL/6 mice using isolectin IB4 as the control of vasculature staining. In the retina, Ly6c expression was analyzed qualitatively and quantitatively in intact, ischemic, and contralateral retinas from 0 to 30 days after the insult. Ly6c expression was observed in all organs and tissues tested, with a brighter signal and more homogeneous staining than the IB4. In the retinas, Ly6c was well expressed, allowing a detailed study of their anatomy. The three retinal plexuses were morphologically different, and from the superficial to the deep one occupied 15 ± 2, 24 ± 7, and 38 ± 1.4 percent of the retinal surface, respectively. In the injured retinas, there was extravasation of the classically activated monocyte/macrophages (Ly6chigh) and the formation of new vessels in the superficial plexus, increasing the area occupied by it to 25 ± 1%. In the contralateral retinas, the superficial plexus area decreased gradually, reaching significance at 30 days, and Ly6c expression progressively disappeared in the intermediate and deep plexuses. Although the role of Ly6c in vascular endothelial cell function is still not completely understood, we demonstrate here that Ly6c can be used as a new specific marker of the mouse vasculature and to assess, qualitatively and quantitatively, vascular changes in health and disease.Entities:
Keywords: cell extravasation; ischemia; vascular plexus; vessels
Mesh:
Substances:
Year: 2021 PMID: 35008441 PMCID: PMC8744623 DOI: 10.3390/ijms23010019
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Markers to identify mouse blood vessels.
| Marker | Target | Characteristics | References |
|---|---|---|---|
| Isolectin-IB4 | Terminal α-d-galactosyl residues | Binds to blood vessels and to activated microglial cells | [ |
| CD31 (cluster of differentiation 31) also known as PECAM-1 (platelet endothelial cell adhesion molecule) | Adhesion molecule that constitutes a large part of the intercellular junctions of endothelial cells | It is found on endothelial cells, platelets, Kupffer cells, macrophages, granulocytes, lymphocytes, megakaryocytes, osteoclasts, and in certain tumors | [ |
| ICAM2 (intercellular adhesion molecule 2) also known as CD102 (cluster of differentiation 102) | Type I transmembrane glycoprotein present in the apical/luminal endothelial cell membrane | ICAM2 masks highlight vessel segments undergoing remodeling. It mediates adhesive interactions important for antigen-specific immune response | [ |
| CLDN5 (claudin 5) | It is one of the six high abundant tight junction proteins in the blood–brain barrier in vivo and the dominant one in vitro | Transiently expressed in the retinal pigment epithelium (RPE) during development, where its expression correlates with permeability changes in the developing RPE | [ |
| ColIV or Col4 (collagen IV) | One of the main components of the basement membrane (BM), a specialized extracellular matrix that compartmentalizes tissues, provides structural support, and influences cell behavior and signaling | Collagen IV is the most abundant structural BM component and is essential for BM integrity but not initial BM formation | [ |
| Endoglin (ENG) also known as CD105 | Transmembrane glycoprotein that functions as a coreceptor for ligands of the transforming growth factor-β superfamily. It is predominantly expressed by activated endothelial cells | It is a facilitator of ligand binding and has a crucial role in angiogenesis. It is also a marker of mesenchymal stem cells and it is expressed in progenitor cells involved in vascular remodeling in animal models | [ |
| ZO-1 (zonula occludens-1) also known as TJP1 (tight junction protein-1) | One of the proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells (endothelial cell–cell junctions) | Is thought to have both structural and signaling roles. It can also associate with claudin, occludin, and F-actin, at tight junction stands, where it provides a linkage between the actin cytoskeleton and the tight junction | [ |
| CDH5 (cadherin 5) also known as VE-cadherin | It is a strictly endothelial specific adhesion molecule located at junctions between endothelial cells and promotes homotypic cell-to-cell interaction | It is vital for the maintenance and control of endothelial cell contacts. It is relevant for the control of vascular permeability and leukocyte extravasation and regulates various cellular processes such as cell proliferation and apoptosis and modulates vascular endothelial growth factor receptor functions. It is essential during embryonic angiogenesis | [ |
| Erg (ETS-related gene) | It is expressed in the nuclei of endothelial cells | It is a transcription factor that has been linked to angiogenesis and to the promotion of vascular stability | [ |
| Dextran-fluorophore (complex branched glucan labelled with a fluorophore) | Blood vessel lumen | Used for intravascular perfusion. High-molecular-weight FITC-dextran remains in the vasculature without diffusion | [ |
| gel-BSA-FITC (gel-bovine serum albumin-fluorescein isothiocyanate) | Blood vessel lumen | Used for intravascular perfusion. The high molecular weight of albumin prevents the marker from crossing blood vessel walls, which ensures the confinement of the fluorescent signal within the blood vessels | [ |
Figure 1Ly6c is expressed in mouse blood vessels. (A) Ly6c (red) and IB4 (purple) detection in several tissues showing Ly6c signal in the brain, intestine, kidney, heart, and tail. The arrow points to blood vessels, and the asterisk to macrophages in the intestinal villi. Nuclei are counterstained with DAPI (blue). (B) Ly6c (purple) and CD115 (red) double immunodetection in non-perfused and perfused retinas. Scale bar is the same for all panels.
Figure 2Comparison of Ly6c and IB4 vascular staining in the retina. (A–C) Photomontage of a representative intact retina showing Ly6C ((A), red), IB4 ((B), purple) and both signals (C) in the ganglion cell layer. (D–G) Magnifications from the central (D,F) and peripheral (E,G) retina are from the yellow squares in (C). Scale bar in (C) for (A–C) images, and in (F) for (D–G) panels.
Figure 3Retinal vascular plexuses. (A) Left: Ly6c immunodetection (red) in a retinal cross-section counterstained with DAPI (blue). Right: drawing depicting the retinal layers and the position of each vascular plexus. RGCL: retinal ganglion cell layer, IPL: inner plexiform layer, INL: inner nuclear layer, OPL: outer plexiform layer, ONL: outer nuclear layer. (B) Whole-mounted retina showing Ly6c staining in the three retinal vascular plexuses. Below each one there are magnifications from the two regions framed in yellow. 1 mm and 100 µm scale bars are for photomontages and magnifications, respectively.
Figure 4Changes in the retinal vasculature after transient ischemia. (A) Ly6c immunodetection showing the superficial plexus (P1) of ischemic retinas analyzed from 0 h (immediately after) to 30 days after the induction of the ischemia. Below each photomontage are shown magnifications of the optic nerve head or retinal periphery. (B) Bar graphs showing the area fraction of the retina covered by P1 ± standard deviation in intact and contralateral retinas. * Significant compared to intact retinas (p < 0.05, Kruskal–Wallis, Dunn’s multiple comparisons test). 1 mm and 100 µm scale bars are for photomontages and magnifications, respectively.
Figure 5Extravasation of classically activated monocyte/macrophages early after the induction of transient ischemia. Ly6c expression in the superficial plexus around the optic nerve head and in the periphery of intact retinas and retinas analyzed 24 h and 3 days after the ischemia. Arrows point to extravasated classically activated monocytes/macrophages.
Figure 6Retinal thinning after ischemia. Confocal images showing Ly6c signal in the three plexuses from 0 h to 30 days after the induction of the ischemia. To the left of each magnification is shown the z-stack spanning the retinal thickness (DAPI in blue) and a magnification of the z-stack (yellow square) where the ganglion cell layer is positioned a 0 µm in all images.
Figure 7Changes in the retinal vasculature of the contralateral uninjured retinas. (A) Ly6c immunodetection showing the superficial plexus (P1) of contralateral retinas analyzed from 0 h (immediately after) to 30 days after the induction of the ischemia. Below each photomontage are shown magnifications of the optic nerve head or retinal periphery. (B) Bar graphs showing the area fraction of the retina covered by P1 ± standard deviation in intact and contralateral retinas. * Significant compared to intact retinas (p < 0.05, Kruskal–Wallis, Dunn’s multiple comparisons test). 1 mm and 100 µm scale bars are for photomontages and magnifications, respectively.
Figure 8Loss of Ly6c expression in the intermediate and deep vascular plexuses of the contralateral uninjured retinas. Confocal images showing Ly6c signal in the three plexuses from 0 h to 30 days after the induction of the ischemia. To the left of each magnification is shown the z-stack spanning the retinal thickness (DAPI in blue) and a magnification of the z-stack (yellow square) where the ganglion cell layer is positioned a 0 µm in all images.
Figure 9Microglial activation in the injured retinas and down-regulation of Ly6c in the contralateral ones. Confocal images showing Ly6c and IB4 staining in the three vascular plexuses of injured and contralateral retinas analyzed at 3 and 30 days after the induction of the ischemia, respectively.